2012-08-10T14:24:33-05:00 2011-12-31 221430039 SOBEL AND CO LLC CPA'S 293 EISENHOWER PARKWAY LIVINGSTON NJ 070391711 990 2011-01-01 820547746 LIFE RAFT GROUP INC LIFE 9738379092 155 ROUTE 46 WEST NO 2ND FL WAYNE NJ 07470 NORMAN J SCHERZER 9738379092 2012-08-10 1 RON MATAN P01277732 9739949494 2012-08-10 2011 2016-02-24 21:20:13Z NORMAN J SCHERZER 155 ROUTE 46 WEST 2ND FLOOR WAYNE NJ 07470 1599032 0 X WWW.LIFERAFTGROUP.ORG X 2002 NJ THE MISSION OF THE LIFE RAFT GROUP IS TO ENSURE SURVIVAL OF GIST PATIENTS THROUGH A COMPREHENSIVE APPROACH CONNECTING INDIVIDUAL PATIENTS' NEEDS, THE WORLDWIDE COMMUNITY OF GIST ADVOCATES AND THE GLOBAL HEALTH AND RESEARCH ENVIRONMENT. 14 13 20 4 0 0 2740321 1506315 0 0 36782 26067 61851 47321 2838954 1579703 1673043 1685000 0 0 728117 886183 0 0 51470 434157 403210 2835317 2974393 3637 -1394690 5898418 4501557 87790 85619 5810628 4415938 X THE MISSION OF THE LIFE RAFT GROUP (LRG) IS TO ENSURE SURVIVAL OF GIST PATIENTS WHILE MAINTAINING THE QUALITY OF THEIR LIVES. TO ACCOMPLISH THIS MISSION, THE LIFE RAFT GROUP DEVOTES ITS EFFORTS TO FIVE MAJOR AREAS: RESEARCH, TREATMENT, SURVEILLANCE, INFORMATION & SUPPORT, PATIENT OUTREACH & ASSISTANCE, AND ADVOCACY. 0 0 2665572 RESEARCH: THE LIFE RAFT GROUP HAS A SIMPLE FOCUS: TO CUREA FORM OF CANCER - GIST (GASTROINTESTINAL STROMAL TUMORS) - AND TO HELP THOSE LIVING WITH IT UNTIL THEN. TO ACHIEVE THIS, WE FUND AND MANAGE UNIQUELY COORDINATED RESEARCH INITIATIVES THAT ALWAYS KEEP THE NEEDS OF THE GIST PATIENT FOREMOST. THE LIFE RAFT GROUP IS THE ONLY GIST ADVOCACY ORGANIZATION WITH A DEDICATED RESEARCH INITIATIVE LED BY A TEAM OF WORLD RENOWNED SCIENTISTS AND CLINICIANS IN GIST. OUR INITIATIVES ARE CONTSTANTLY ANALYZED TO ENSURE THEIR FOCUS REMAINS ON FINDING A CURE FOR GIST. 154411 INFORMATION, EDUCATION AND SUPPORT: THE LIFE RAFT GROUP HAS A SIMPLE FOCUS: TO CURE A FORM OF CANCER - GIST (GASTROINTESTINAL STROMAL TUMORS) - AND TO HELP THOSE LIVING WITH IT UNTIL THEN.THE LRG PROVIDES SUPPORT & EDUCATION TO PATIENTS & CAREGIVERS LIVING WITH GIST ON AN INDIVIDUAL BASIS BY PROVIDING ONE-ON-ONE COUNSELING SESSIONS, LOCAL IN-PERSON MEETINGS, A BIENNIAL MEETING THAT GATHERS THE PATIENT, PHARMACUETICAL & MEDICAL PROFESSIONAL COMMUNITIES TOGETHER IN A SUPPORTIVE AND EDUCATIONAL SETTING. WE ALSO OFFER EDUCATION TO THE GIST COMMUNITY AT LARGE THROUGH OUR VIDEOS & WEBINARS, WEBSITES, WORLDWIDE GIST SPECIALIST DATABASE, A ONE-OF-A-KIND GIST-SPECIFIC CLINICAL TRIALS DATABASE, NEWSLETTERS & OTHER MATERIALS. 51470 ADVOCACY: THE LIFE RAFT GROUP HAS A SIMPLE FOCUS: TO CURE A FORM OF CANCER - GIST (GASTROINTESTINAL STROMAL TUMORS) - AND TO HELP THOSE LIVING WITH IT UNTIL THEN.THE LRG IS A VERY ACTIVE PRESENCE IN EFFECTING CHANGE IN THE GIST COMMUNITY. OUR ADVOCACY ROLE RANGES FROM HELPING PATIENTS WITH TREATMENT ACCESS ISSUES ON A ONE-ON-ONE BASIS, CREATING REGIONAL GROUPS IN UNDERSERVED AREAS IN ORDER TO BETTER INFORM & EMPOWER PATIENTS, CHAMPIONING PATIENTS' NEEDS BEFORE GOVERNMENT & POLICY MAKERS AND REPORTING ON TRENDS IN DOSAGE AND SURVIVAL TO THE WORLD. 2871453 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 1 20 1 0 0 0 0 0 1 1 0 0 X 14 13 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NJ X X NORMAN J SCHERZER 9738379092 155 ROUTE 46 WEST 2ND FL WAYNE NJ 07470 JERRY CUDZIL 1.00 X 0 0 0 RAYMOND MONTAGUE 1.00 X 0 0 0 ROBERT BOOK 1.00 X 0 0 0 STANN BUNN 1.00 X 0 0 0 JIM HUGHES 1.00 X 0 0 0 GERALD KNAPP 1.00 X 0 0 0 JOHN POSS 1.00 X 0 0 0 MARIETTA ROBINSON 1.00 X 0 0 0 RODRIGO SALAS 1.00 X 0 0 0 SILVIA WILLIAMS-STEINHILBER 1.00 X 0 0 0 CHRIS CARLEY 1.00 X 0 0 0 LAWRENCE D SELKOVITS 1.00 X 0 0 0 NORMAN J SCHERZER 35.00 X X 98377 0 8853 DAVID SAFFORD 1.00 X 0 0 0 98377 0 8853 0 0 0 0 0 28758 1477557 1506315 26067 26067 66650 28758 19329 47321 47321 1579703 0 0 73388 1685000 1685000 108231 97407 5412 5412 622012 574418 23797 23797 15900 14628 636 636 67998 62558 2720 2720 72042 66278 2882 2882 97352 89564 3894 3894 81015 74535 3240 3240 1516 1394 61 61 82529 75927 3301 3301 103776 95474 4151 4151 20474 18836 819 819 8800 8096 352 352 MARKETING AND PR 4974 4576 199 199 MISCELLANEOUS 2774 2762 6 6 2974393 2871453 51470 51470 11988 3407 5805690 4334805 97500 7475 21817 117850 74835 58314 43015 1013 14951 5898418 4501557 87790 85619 87790 85619 X 5810628 4415938 5810628 4415938 5898418 4501557 -1394690 0 X X 0 1 1 X 0 X 749685 947608 2960796 717871 1435028 6810988 749685 947608 2960796 717871 1435028 6810988 2253209 4557779 84889 104796 53529 36782 26067 306063 16136 16136 7133187 51783 0.63900 0.61410 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 117850 74835 43015 43015 1579703 2974393 -1394690 -1394690 1579703 0 1579703 0 1579703 2974393 0 2974393 0 2974393 DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48: PART X: THE ORGANIZATION IS EXEMPT FROM FEDERAL AND STATE INCOME TAXES UNDER SECTION 501(C) (3) OF THE INTERNAL REVENUE CODE. THE ORGANIZATION FOLLOWS ACCOUNTING STANDARDS THAT PROVIDE CLARIFICATION ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN THE ORGANIZATION'S FINANCIAL STATEMENTS. THE GUIDANCE PRESCRIBES A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, AND ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE AND TRANSITION. TAX RETURNS FOR CERTAIN YEARS ARE SUBJECT TO AUDIT BY FEDERAL AND STATE JURISDICTIONS. AT DECEMBER 31, 2011, THERE ARE NO SIGNIFICANT INCOME TAX UNCERTAINTIES THAT ARE EXPECTED TO HAVE A MATERIAL IMPACT ON THE ORGANIZATION'S 2011 FINANCIAL STATEMENTS. 1 EUROPE 0 0 GRANTS TO RECIPIENTS IN REGION. PROGRAM FUNDING FOR RESEARCH FOR GIST PATIENTS. 225000 0 0 0 0 0 0 225000 0 225000 X EUROPE TO CONDUCT RESEARCH TO DISCOVER REASONS FOR TREATMENT RESISTANCE. 112500 WIRE TRANSFER EUROPE TO CONDUCT RESEARCH TO DISCOVER REASONS FOR TREATMENT RESISTANCE. 112500 WIRE TRANSFER 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: THE GRANT RECIPIENTS MUST SUBMIT REGULAR PROGRESS REPORTS, BUDGET REPORTS AND COPIES OF ARTICLES AND PRESENTATIONS IN WHICH THE PRINCIPAL INVESTIGATOR IS LISTED AS THE AUTHOR, AS WELL AS PARTICIPATE IN A SPECIFIED NUMBER OF IN-PERSON AND TELECONFERENCE MEETINGS EVERY TWELVE MONTHS. METHOD USED TO ACCCOUNT FOR EXPENDITURES: SCHEDULE F, PART I, LINE 3: WIRE TRANSFER GALA 95408 28758 66650 1263 5115 9351 3600 95408 28758 66650 1263 5115 9351 3600 19329 47321 1 UNIVERSITY OF PITTSBURGH 5117 CENTRE AVENUE PITTSBURGH PA 15213 250965591 501(C)(3) 162500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. PORTLAND VA RESEARCH FOUNDATION 3710 US VETERANS HOSPITAL ROAD PORTLAND OR 97201 943090170 501(C)(3) 157500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. CLEVELAND CLINIC 9500 EUCLID AVENUE L25 CLEVELAND OH 44195 340714575 501(C)(3) 337500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10021 912154267 501(C)(3) 50000 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. STANFORD UNIVERSITY 300 PASTEUR DRIVE L-225 STANFORD CA 94305 941156365 501(C)(3) 137500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. BRIGHAM & WOMEN'S HOSPITAL 75 FRANCIS STREET THORN 5TH FLOOR BOSTON MA 02115 042312909 501(C)(3) 417500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. PORTLAND VA RESEARCH FOUNDATION PO BOX 69539 PORTLAND OR 97239 943090170 501(C)(3) 147500 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. MAYO CLINIC 200 1ST ST SOUTHWEST ROCHESTER MN 55905 999999999 501(C)(3) 50000 TO CONDUCT RESEARCH REGARDING TREATMENT RESISTANCE IN GIST PATIENTS. PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: THE GRANT RECIPIENTS MUST SUBMIT REGULAR PROGRESS REPORTS, BUDGET REPORTS AND COPIES OF ARTICLES AND PRESENTATIONS IN WHICH THE PRINCIPAL INVESTIGATOR IS LISTED AS THE AUTHOR, AS WELL AS PARTICIPATE IN A SPECIFIED NUMBER OF IN-PERSON AND TELECONFERENCE MEETINGS EVERY TWELVE MONTHS. FORM 990, PART VI, SECTION B, LINE 11 FORM 990 IS FIRST REVIEWED BY THE DIRECTOR OF ADMINISTRATION, THEN BY THE EXECUTIVE DIRECTOR AFTER DISCUSSION WITH THE DIRECTOR OF ADMINISTRATION. IT IS ALSO SENT TO THE BOARD TREASURER AND THE BOARD PRESIDENT AND ANY QUESTIONS OR COMMENTS ARE DISCUSSED WITH THE EXECUTIVE DIRECTOR AND DIRECTOR OF ADMINISTRATION. FORM 990, PART VI, SECTION B, LINE 12C POTENTIAL CONFLICTS ARE DISCUSSED ANNUALLY AT A BOARD MEETING. FORM 990, PART VI, SECTION B, LINE 15 AT LEAST ONCE A YEAR THE EXECUTIVE DIRECTOR MEETS TO REVIEW AND DISCUSS REPORTS OF COMPARABLE NON-PROFIT SALARIES PREPARED BY INDEPENDENT ORGANIZATIONS. THIS REVIEW PROVIDES THE GUIDELINES FOR REVIEWING AND APPROVING ANY SALARY RECOMMENDATIONS PROPOSED BY THE EXECUTIVE DIRECTOR. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION MAKES ITS FORM 1023 AND 990 AVAILABLE FOR PUBLIC INSPECTION THROUGH THE ORGANIZATION'S WEBSITE, AT ANOTHER'S WEBSITE CALLED GUIDESTAR.COM AND UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, INCLUDING A CONFLICT OF INTEREST POLICY (PART OF BY-LAWS), AND FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE AND ARE MADE AVAILABLE AS INDIVIDUAL DOCUMENTS UPON REQUEST. FORM 990, PART XII, LINE 2C NO CHANGE FROM PRIOR YEAR.